Maxim Withdraws Ceplene Advanced Malignant Melanoma NDA
This article was originally published in The Pink Sheet Daily
Executive Summary
The company is shifting its focus for Ceplene to acute myeloid leukemia. Melanoma patients enrolled in the confirmatory Phase III trial will be allowed to complete their treatment regimen under a compassionate use program.